Louise Chen's Stock Ratings

Cantor Fitzgerald Analyst

Louise Chen is an analyst at Cantor Fitzgerald. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

8.14%

Smart Score

67.1%

Overall Average Return Percentile

55th

Number of Ratings

179
Buy NowGet Alert
05/17/2024ABBVBuy Now
AbbVie
$163.0222.68% → $200Initiates → OverweightGet Alert
05/14/2024ATOSBuy Now
Atossa Therapeutics
$1.62——Reiterates → OverweightGet Alert
05/09/2024PCVXBuy Now
Vaxcyte
$74.16——Reiterates → OverweightGet Alert
05/09/2024PDSBBuy Now
PDS Biotechnology
$3.33——Reiterates → OverweightGet Alert
05/06/2024JNJBuy Now
Johnson & Johnson
$151.0642.33% → $215ReiteratesOverweight → OverweightGet Alert
05/01/2024LLYBuy Now
Eli Lilly and Co
$803.9810.08%$815 → $885MaintainsOverweightGet Alert
04/30/2024LLYBuy Now
Eli Lilly and Co
$803.9810.08%$815 → $885ReiteratesOverweight → OverweightGet Alert
04/25/2024CDTXBuy Now
Cidara Therapeutics
$11.00——Reiterates → OverweightGet Alert
04/23/2024CDTXBuy Now
Cidara Therapeutics
$11.00——Reiterates → OverweightGet Alert
04/18/2024PFEBuy Now
Pfizer
$28.4158.37% → $45ReiteratesOverweight → OverweightGet Alert
04/18/2024NVOBuy Now
Novo Nordisk
$134.5618.9% → $160ReiteratesOverweight → OverweightGet Alert
04/18/2024MRKBuy Now
Merck & Co
$131.023.04% → $135ReiteratesOverweight → OverweightGet Alert
04/18/2024LLYBuy Now
Eli Lilly and Co
$803.981.37% → $815ReiteratesOverweight → OverweightGet Alert
04/17/2024JNJBuy Now
Johnson & Johnson
$151.0642.33% → $215ReiteratesOverweight → OverweightGet Alert
04/15/2024LLYBuy Now
Eli Lilly and Co
$803.981.37% → $815ReiteratesOverweight → OverweightGet Alert
04/15/2024REGNBuy Now
Regeneron Pharmaceuticals
$991.15-6.67% → $925ReiteratesNeutral → NeutralGet Alert
04/15/2024PFEBuy Now
Pfizer
$28.4158.37% → $45ReiteratesOverweight → OverweightGet Alert
04/15/2024JNJBuy Now
Johnson & Johnson
$151.0642.33% → $215ReiteratesOverweight → OverweightGet Alert
04/05/2024PFEBuy Now
Pfizer
$28.4158.37% → $45ReiteratesOverweight → OverweightGet Alert
04/05/2024NVOBuy Now
Novo Nordisk
$134.5618.9% → $160ReiteratesOverweight → OverweightGet Alert
04/05/2024MRKBuy Now
Merck & Co
$131.023.04% → $135ReiteratesOverweight → OverweightGet Alert
04/05/2024LLYBuy Now
Eli Lilly and Co
$803.981.37% → $815ReiteratesOverweight → OverweightGet Alert
04/04/2024SPROBuy Now
Spero Therapeutics
$1.53——Reiterates → OverweightGet Alert
04/01/2024PFEBuy Now
Pfizer
$28.4158.37% → $45ReiteratesOverweight → OverweightGet Alert
04/01/2024NVOBuy Now
Novo Nordisk
$134.5618.9% → $160ReiteratesOverweight → OverweightGet Alert
04/01/2024MRKBuy Now
Merck & Co
$131.023.04% → $135ReiteratesOverweight → OverweightGet Alert
04/01/2024LLYBuy Now
Eli Lilly and Co
$803.981.37% → $815ReiteratesOverweight → OverweightGet Alert
04/01/2024SCYXBuy Now
SCYNEXIS
$2.71——Reiterates → OverweightGet Alert
04/01/2024ZVRABuy Now
Zevra Therapeutics
$4.62——Reiterates → OverweightGet Alert
03/27/2024MRKBuy Now
Merck & Co
$131.023.04% → $135ReiteratesOverweight → OverweightGet Alert

Recent Analyst Stock Rating News

The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
What 23 Analyst Ratings Have To Say About Eli Lilly and Co
Unveiling 17 Analyst Insights On Merck & Co
Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results
Johnson & Johnson (NYSE: JNJ) reported better-than-expected first-quarter earnings on Tuesday.
Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson (NYSE: JNJ) is set to release earnings results for its first quarter before the opening bell on April 16, 2024.
A Closer Look at 9 Analyst Recommendations For Johnson & Johnson
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Amazon, Alphabet And A Pharmaceutical Giant: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners said Amazon.com, Inc. (NASDAQ: AMZN) is on the 
Assessing Novo Nordisk: Insights From 10 Financial Analysts
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free